SRPT Stock Analysis: Buy, Sell, or Hold?
SRPT - Sarepta Therapeutics,, Inc. Common Stock
$19.28
1.08 (5.93%)
▲
5d:
+20.35%
30d:
+18.65%
90d:
-12.88%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 5.9/10
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: SRPT is 8.8% above its trading range ($17.72). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: SRPT is 8.8% above its trading range ($17.72). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.74
Based on -19.0% avg growth
INTRINSIC VALUE TODAY
$3.56
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $19.28, which is considered extended relative to its 30-day fair value range of $15.68 to $17.72. The stock's valuation (Forward PE: 7.1) is in line with its historical norms (6.7). At these levels, the market is pricing in 1.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is approaching resistance at $19.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: SRPT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $22.00 (+14.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is approaching resistance at $19.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: SRPT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $22.00 (+14.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.68 -
$17.72
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
Protect Your Profits
Holding SRPT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+8.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading below Wall St target ($22.00)
- NEUTRAL: Market pricing in 1.9% annual earnings growth - fairly valued
- CAUTION: Extended 8.8% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$15.68 -
$17.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$15.79
Resistance Level
$19.56
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.07
Wall Street Target
$22.00
(+14.1%)
Revenue Growth (YoY)
-1.9%
Earnings Growth (YoY)
2663.8%
Profit Margin
3.0%
Valuation Premium vs History
+1.9% premium
PE vs Historical
7.1 vs 6.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.9%
(market-implied from PE analysis)
1-Year Target
$19.65
(+2%)
2-Year Target
$20.02
(+4%)
3-Year Target
$20.40
(+6%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$19.33
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -42.0%)
$43.29
(+125%)
Base:
(SPY PE: 7.1, Growth: -42.0%)
$14.06
(-27%)
Bear:
(PE: 6.0, Growth: -42.0%)
$11.95
(-38%)
📈
Valuation based on Current Earnings
Forward PE: 5.30 | Forward EPS (Implied): $3.64
Bull Case
$23.28
(+21%)
Analyst growth 15.0%, PE expands to 5.6
Base Case
$19.28
(0%)
Market implied 0.0%, PE stable at 5.3
Bear Case
$14.75
(-24%)
Severe decline -15.0%, PE contracts to 4.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Mayo
SELL
7239 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
